This “Dihydroorotate Dehydrogenase (DHODH) Inhibitor - Pipeline Insight, 2024” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Dihydroorotate Dehydrogenase (DHODH) Inhibitor pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
PTC 299: PTC Therapeutics Emvododstat (formerly PTC 299) is an oral, small molecule tablet that inhibits the cellular enzyme DHODH. The drug is in Phase II/III clinical studies for COVID 2019 infections and in Phase I for Acute myeloid leukaemia.
This product will be delivered within 2 business days.
Geography Covered
- Global coverage
Dihydroorotate Dehydrogenase (DHODH) Inhibitor Understanding
Dihydroorotate Dehydrogenase (DHODH) Inhibitor: Overview
Dihydroorotate dehydrogenase (DHODH), a novel enzyme, involved in the biosynthesis of uridine. Dihydroorotate dehydrogenases are grouped into Class 1 and Class 2, according to sequence similarity, subcellular location and substrate preference. This protein is a mitochondrial protein located on the outer surface of the inner mitochondrial membrane (IMM). DHODH enzyme is proven to play an active role in cancer and immunological disorders such as acute myeloid leukemia, RA, multiple sclerosis. Inhibitors of DHODH block the synthesis of pyrimidine-based nucleotides and are known to potentially possess wide applications as chemotherapeutic agents. Suppression of the DHODH enzyme in humans is a proven treatment method for immune disorders, especially cancer, RA (Leflunomide) and multiple sclerosis (Teriflunomide). There are a number of clinical trials underway for COVID-19 treatment using DHODH inhibitors.Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Dihydroorotate Dehydrogenase (DHODH) Inhibitor R&D. The therapies under development are focused on novel approaches for Dihydroorotate Dehydrogenase (DHODH) Inhibitor.Dihydroorotate Dehydrogenase (DHODH) Inhibitor Emerging Drugs Chapters
This segment of the Dihydroorotate Dehydrogenase (DHODH) Inhibitor report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.Dihydroorotate Dehydrogenase (DHODH) Inhibitor Emerging Drugs
IMU-838: Immunic IMU-838 is a small molecule, oral tablet formulation based investigational drug that inhibits dihydroorotate dehydrogenase (DHODH) enzyme. IMU-838 is under clinical development for the treatment of relapsing-remitting multiple sclerosis, or RRMS, inflammatory bowel disease, or IBD, and other chronic inflammatory and autoimmune diseases. The drug is in Phase II/III clinical evaluation for the treatment of COVID 2019infections.PTC 299: PTC Therapeutics Emvododstat (formerly PTC 299) is an oral, small molecule tablet that inhibits the cellular enzyme DHODH. The drug is in Phase II/III clinical studies for COVID 2019 infections and in Phase I for Acute myeloid leukaemia.
Dihydroorotate Dehydrogenase (DHODH) Inhibitor: Therapeutic Assessment
This segment of the report provides insights about the different Dihydroorotate Dehydrogenase (DHODH) Inhibitor drugs segregated based on following parameters that define the scope of the report, such as:Major Players working on Dihydroorotate Dehydrogenase (DHODH) Inhibitor
There are approx. 10+ key companies which are developing the Dihydroorotate Dehydrogenase (DHODH) Inhibitor. The companies which have their Dihydroorotate Dehydrogenase (DHODH) Inhibitor drug candidates in the most advanced stage, i.e. Phase II/III include, ImmunicPhases
This report covers around 10+ products under different phases of clinical development like- Late-stage products (Phase III and
- Mid-stage products (Phase II and
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
Route of Administration
Dihydroorotate Dehydrogenase (DHODH) Inhibitor pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Intravaginal
- Oral
- Parenteral
- Subcutaneous
- Topical
Molecule Type
Products have been categorized under various Molecule types such as
- Vaccines
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.Dihydroorotate Dehydrogenase (DHODH) Inhibitor: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Dihydroorotate Dehydrogenase (DHODH) Inhibitor therapeutic drugs key players involved in developing key drugs.Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Dihydroorotate Dehydrogenase (DHODH) Inhibitor drugs.Dihydroorotate Dehydrogenase (DHODH) Inhibitor Report Insights
- Dihydroorotate Dehydrogenase (DHODH) Inhibitor Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Dihydroorotate Dehydrogenase (DHODH) Inhibitor Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Key Questions
Current Scenario and Emerging Therapies:- How many companies are developing Dihydroorotate Dehydrogenase (DHODH) Inhibitor drugs?
- How many Dihydroorotate Dehydrogenase (DHODH) Inhibitor drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for Dihydroorotate Dehydrogenase (DHODH) Inhibitor?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Dihydroorotate Dehydrogenase (DHODH) Inhibitor therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Dihydroorotate Dehydrogenase (DHODH) Inhibitor and their status?
- What are the key designations that have been granted to the emerging drugs?
Key Players
- Sanofi
- Immunic
- PTC Therapeutics
- Clear Creek Bio
- Eye GatePharma
- ASLAN Pharmaceuticals
- Medicines for Malaria Venture
Key Products
- Teriflunomide
- IMU-838
- Emvododstat
- Olorofim
- Brequinar
- PP 001 Eye GatePharma
- ASLAN-003
- MMV-1793609
This product will be delivered within 2 business days.
Table of Contents
IntroductionExecutive SummaryDihydroorotate Dehydrogenase (DHODH) Inhibitor - Analytical PerspectiveDrug profiles in the detailed report…..Drug profiles in the detailed report…..Drug profiles in the detailed report…..Drug profiles in the detailed report…..Dihydroorotate Dehydrogenase (DHODH) Inhibitor Key CompaniesDihydroorotate Dehydrogenase (DHODH) Inhibitor Key ProductsDihydroorotate Dehydrogenase (DHODH) Inhibitor- Unmet NeedsDihydroorotate Dehydrogenase (DHODH) Inhibitor- Market Drivers and BarriersDihydroorotate Dehydrogenase (DHODH) Inhibitor- Future Perspectives and ConclusionDihydroorotate Dehydrogenase (DHODH) Inhibitor Analyst ViewsDihydroorotate Dehydrogenase (DHODH) Inhibitor Key CompaniesAppendix
Dihydroorotate Dehydrogenase (DHODH) Inhibitor: Overview
Pipeline Therapeutics
Therapeutic Assessment
In-depth Commercial Assessment
Dihydroorotate Dehydrogenase (DHODH) Inhibitor Collaboration Deals
Late Stage Products (Phase III)
Drug name: Company name
Mid Stage Products (Phase II/III)
IMU-838: Immunic
Early Stage Products (Phase I/II)
PP 001: EyeGate Pharma
Pre-clinical and Discovery Stage Products
MMV-1793609: Medicines for Malaria Venture
Inactive Products
List of Tables
List of Figures
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Sanofi
- Immunic
- PTC Therapeutics
- Clear Creek Bio
- EyeGate Pharma
- ASLAN Pharmaceuticals
- Medicines for Malaria Venture